These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16849895)

  • 1. The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions.
    Sander GE; Giles TD
    Am J Geriatr Cardiol; 2006; 15(4):255-9. PubMed ID: 16849895
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 4. [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].
    Bramlage P; Böcking W; Kirch W
    Dtsch Med Wochenschr; 2005 Mar; 130(12):665-8. PubMed ID: 15776349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Selective cannabinoid receptor antagonists].
    Kreutz S; Korf HW; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2006; 35(6):512-20. PubMed ID: 17137082
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
    Mach F; Montecucco F; Steffens S
    Pharmacol Rep; 2009; 61(1):13-21. PubMed ID: 19307689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction.
    Woods SC
    JAAPA; 2007 Nov; Suppl Endocannabinoid():7-10. PubMed ID: 18047036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rimonabant: new data and emerging experience.
    Wright SM; Dikkers C; Aronne LJ
    Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development. Drugs inspired by a drug.
    Marx J
    Science; 2006 Jan; 311(5759):322-5. PubMed ID: 16424309
    [No Abstract]   [Full Text] [Related]  

  • 10. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
    Patti ME
    J Clin Invest; 2010 Aug; 120(8):2646-8. PubMed ID: 20664166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of the endocannabinoid system for the reduction of cardiometabolic risk factors.
    Samaha FF; Chou CM
    Obesity (Silver Spring); 2009 Feb; 17(2):220-5. PubMed ID: 19039319
    [No Abstract]   [Full Text] [Related]  

  • 14. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
    Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
    Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
    Wierzbicki AS
    Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid system: potential for reducing cardiometabolic risk.
    Ginsberg HN; Woods SC
    Obesity (Silver Spring); 2009 Oct; 17(10):1821-9. PubMed ID: 19373218
    [No Abstract]   [Full Text] [Related]  

  • 17. The challenge of treating obesity: the endocannabinoid system as a potential target.
    Isoldi KK; Aronne LJ
    J Am Diet Assoc; 2008 May; 108(5):823-31. PubMed ID: 18442506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors].
    Sulcová A
    Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid system as a target for obesity treatment.
    Aronne LJ; Pagotto U; Foster GD; Davis SN
    Clin Cornerstone; 2008; 9(1):52-64; discussion 65-6. PubMed ID: 19046740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.